Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asta Medica Cetrotide Approved For Single- And Multiple-Dose Regimens

Executive Summary

Asta Medica's Cetrotide (cetrorelix) controlled ovarian stimulation injection received FDA approval for a 3 mg single-dose regimen and a .25 mg multiple-dose regimen on Aug. 11.

You may also be interested in...



Part D Off-Label Coverage Should Not Be Limited To Compendia Lists – Lawsuit

Medicare Part D drug plans should be able to consider a variety of evidence supporting off-label uses of drugs, not just the standard medical compendia list of accepted indications, a lawsuit challenging HHS' interpretation of congressional directives on this issue argues

Part D Off-Label Coverage Should Not Be Limited To Compendia Lists – Lawsuit

Medicare Part D drug plans should be able to consider a variety of evidence supporting off-label uses of drugs, not just the standard medical compendia list of accepted indications, a lawsuit challenging HHS' interpretation of congressional directives on this issue argues

Serono Cetrotide

Gonadotropin releasing hormone will be marketed, distributed and sold exclusively by Serono under a deal reached with Asta Medica. The two companies were scheduled to co-promote Cetrotide (cetrorelix) worldwide except for Japan. The NDA, approved Aug. 11, will now be transferred to Serono (1"The Pink Sheet" Aug. 21, p. 10)

Related Content

UsernamePublicRestriction

Register

PS036509

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel